GlassScriptPhysician profile
Megan Becker
NPI 1255813788
$3,246.52
in general payments reported to CMS, 2019-2025
25 companies · $787 in 2025
The $787 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $205 · 2022: $328 · 2023: $812 · 2024: $1,115 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,713.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.07 | 2022-2024 | |
| Axsome Therapeutics, INC. | $458.31 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $316.49 | 2022-2025 | Caplyta |
| Lundbeck LLC | $187.27 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Otsuka America Pharmaceutical, INC. | $168.15 | 2021-2024 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $131.97 | 2021-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $130.28 | 2024 | Cobenfy |
| Alkermes, INC. | $123.06 | 2022-2025 | Aristada, Lybalvi |
| Corium, LLC | $116.45 | 2022-2024 | Azstarys |
| Bausch Health US, LLC | $92.64 | 2021-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $88.75 | 2023-2025 | Xelstrym, Secuado |
| Gilead Sciences, INC. | $84.56 | 2021-2022 | |
| Tris Pharma INC | $74.82 | 2022-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $73.18 | 2023-2025 | Spravato, Invega Sustenna |
| Neos Therapeutics, LP | $71.25 | 2023-2024 | Adzenys Xr-Odt |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $70.62 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $68.27 | 2021 | |
| Ardelyx, INC. | $48.93 | 2023 | Ibsrela |
| Teva Pharmaceuticals USA, INC. | $43.29 | 2023-2024 | Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $33.79 | 2023-2024 | Quviviq |
| Braintree Laboratories, INC. | $27.58 | 2024 | Sutab, Suflave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.10 | 2022 | |
| Almatica Pharma LLC | $21.70 | 2022 | |
| Adlon Therapeutics L.P. | $19.22 | 2021 | |
| Owp Pharmaceuticals, INC. | $16.77 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.